{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T16:31:16Z","timestamp":1775233876223,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/iae.0b013e31826b6763","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T21:12:11Z","timestamp":1354741931000},"page":"740-747","source":"Crossref","is-referenced-by-count":86,"title":["VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB DEPENDS ON THE OPTICAL COHERENCE TOMOGRAPHIC PATTERNS OF PATIENTS WITH DIFFUSE DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"33","author":[{"given":"Masahiko","family":"Shimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210130","first-page":"1796","article-title":"Photocoagulation for diabetic macular edema, report 1.","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R2-8-20210130","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/08820539909069541","article-title":"The pathogenesis of edema in diabetic maculopathy.","volume":"14","author":"Antcliff","year":"1999","journal-title":"Semin Ophthalmol"},{"key":"R3-8-20210130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/1573399054022839","article-title":"Down-regulation of angiogenic inhibitors: a potential pathogenic mechanism for diabetic complications.","volume":"1","author":"Ma","year":"2005","journal-title":"Curr Diabetes Rev"},{"key":"R4-8-20210130","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/112067210801800328","article-title":"Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.","volume":"18","author":"Montero","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"R5-8-20210130","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/IAE.0b013e3181f04991","article-title":". Visual outcome after intravitreal triamcinolone acetonide depends on optical coherence tomographic patterns in patients with diffuse diabetic macular edema.","volume":"31","author":"Shimura","year":"2011","journal-title":"Retina"},{"key":"R6-8-20210130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","article-title":". Primary intravitreal bevacizumab (Avastin) for diabetic macular edema.","volume":"114","author":"Arevalo","year":"2007","journal-title":"Ophthalmology"},{"key":"R7-8-20210130","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/01.iae.0000247165.38655.bf","article-title":". Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema.","volume":"26","author":"Haritoglou","year":"2006","journal-title":"Retina"},{"key":"R8-8-20210130","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(99)00033-1","article-title":"Patterns of diabetic macular edema with optical coherence tomography.","volume":"127","author":"Otani","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"R9-8-20210130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ajo.2006.04.023","article-title":"Optical coherence tomographic patterns of diabetic macular edema.","volume":"142","author":"Kim","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R11-8-20210130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00417-010-1452-4","article-title":"Meta-analysis and review on the effect of bevacizumab in diabetic macular edema.","volume":"249","author":"Goyal","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-8-20210130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000330045","article-title":". Effect of intravitreal bevacizumab injection based on optical coherence tomography patterns of diabetic macular edema.","volume":"226","author":"Kim","year":"2011","journal-title":"Ophthalmologica"},{"key":"R13-8-20210130","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.2337\/diabetes.47.12.1953","article-title":". Vascular permeability in experimental diabetes is associated with reduced endothelial occlusion content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group.","volume":"47","author":"Antonetti","year":"1998","journal-title":"Diabetes"},{"key":"R14-8-20210130","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":". Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.","volume":"331","author":"Aiello","year":"1994","journal-title":"N Eng J Med"},{"key":"R15-8-20210130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","article-title":"Vascular endothelial growth factor (VEGF) and its receptors.","volume":"13","author":"Neufeld","year":"1999","journal-title":"FASEB J"},{"key":"R16-8-20210130","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1517\/13543784.13.10.1275","article-title":". The role of growth factors in the pathogenesis of diabetic retinopathy.","volume":"13","author":"Grant","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"R17-8-20210130","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/S0039-6257(02)00387-9","article-title":". Diabetic retinopathy: more than meets the eye.","volume":"47","author":"Gardner","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"R18-8-20210130","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/359845a0","article-title":"Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.","volume":"359","author":"Plate","year":"1992","journal-title":"Nature"},{"key":"R19-8-20210130","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/359843a0","article-title":"Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.","volume":"359","author":"Shweiki","year":"1992","journal-title":"Nature"},{"key":"R20-8-20210130","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ophtha.2006.06.044","article-title":"Correlation between optical coherence tomography and fluorescein angiography findings in diabetic macular edema.","volume":"114","author":"Otani","year":"2007","journal-title":"Ophthalmology"},{"key":"R21-8-20210130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9394(99)00409-2","article-title":"Tomographic assessment of vitreous surgery for diabetic macular edema.","volume":"129","author":"Otani","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R22-8-20210130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/bjo.79.8.728","article-title":". Non-retinovascular leakage in diabetic maculopathy.","volume":"79","author":"Weinberger","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"R23-8-20210130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ajo.2003.09.016","article-title":"The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema.","volume":"137","author":"Kang","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R24-8-20210130","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/0039-6257(84)90227-3","article-title":"Macular edema: a complication of diabetic retinopathy.","volume":"28","author":"Ferris","year":"1984","journal-title":"Surv Ophthalmol"},{"key":"R25-8-20210130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0014-4835(80)90062-7","article-title":"Early morphological alteration of the pigment epithelium in streptozotocin-induced diabetes: increased surface area of the basal cell membrane.","volume":"30","author":"Grimes","year":"1980","journal-title":"Exp Eye Res"},{"key":"R26-8-20210130","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archopht.1980.01020030719015","article-title":". A permeability defect of the retinal pigment epithelium. Occurrence in early streptozotocin diabetes.","volume":"98","author":"Kirber","year":"1980","journal-title":"Arch Ophthalmol"},{"key":"R28-8-20210130","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","article-title":"A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.","volume":"114","year":"2007","journal-title":"Ophthalmology"},{"key":"R29-8-20210130","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1097\/IAE.0b013e31820bde7d","article-title":". Initial macular thickness and response to treatment in diabetic macular edema.","volume":"31","author":"Soheilian","year":"2011","journal-title":"Retina"},{"key":"R30-8-20210130","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ajo.2007.12.031","article-title":". Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema.","volume":"145","author":"Shimura","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R31-8-20210130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/bjo.2007.129122","article-title":". Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).","volume":"92","author":"Paccola","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R32-8-20210130","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4239\/wjd.v2.i6.98","article-title":"Managing diabetic macular edema: the leading cause of diabetes blindness.","volume":"2","author":"Romeo-Aroca","year":"2011","journal-title":"World J Diabetes"},{"key":"R33-8-20210130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0161-6420(95)31052-4","article-title":"The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema.","volume":"102","author":"Klein","year":"1995","journal-title":"Ophthalmology"},{"key":"R34-8-20210130","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/S0161-6420(89)32699-6","article-title":". The Wisconsin epidemiologic study of diabetic retinopathy XI. The incidence of macular edema.","volume":"96","author":"Klein","year":"1989","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00006982-201304000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:29:56Z","timestamp":1618277396000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201304000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e31826b6763","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}